Hims & Hers Health grew its revenue by 49% last quarter.
The company incurred a loss, however, as its gross margins deteriorated.
Hims & Hers Health (NYSE:HIMS) stock is in free fall. The company reported earnings last week, and the results clearly didn't impress the market. The stock is now down to around the levels it was at in April, and since the start of the year, it has declined by more than 40%.
Was the earnings report really that bad for Hims & Hers stock, or is the market overreacting, and could this instead be a great buying opportunity?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
For its September quarter, Hims & Hers reported impressive revenue growth of 49%, with its top line coming in at 890.4 million. Its subscriber count rose by 13%, and monthly revenue per average subscriber also increased by 30%.
The numbers seemed solid at first glance for the healthcare company, which offers patients access to personalized treatment options, including for GLP-1 drugs. But what's concerning is that although the growth rate is impressive, the company's bottom line isn't nearly as strong.
Hims & Hers incurred an operating loss of $66.1 million, which was a sharp reversal from a year ago when it reported a profit of $11.8 million. Not only were operating expenses higher, which investors would normally expect to see with more revenue, but its gross margin percentage worsened from 74% a year ago to 57% this past quarter. This can be a worrisome sign, as it means a smaller portion of revenue is left after cost of sales to cover its operating costs. This may be due to more aggressive pricing or product mix. Either way, it's not a great sign.
The telehealth company has achieved impressive growth over the years, but with worsening margins and a lack of consistent profitability, the stock is a bit of a risky buy these days. Its financials aren't impressive beyond the top line, and its overall business doesn't have a sustainable competitive advantage that makes it a safe long-term investment to hold on to; its ability to succeed over the long term is by no means a sure thing, and investors shouldn't assume it'll recover from its recent downturn.
Hims & Hers isn't a stock I'd buy, as it requires incredibly high gross margins for the company to turn a profit, and in the most recent quarter, gross margin declined notably. Until and unless the company can demonstrate that it can grow profitably on a reliable basis, I'd avoid the stock.
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.